OncoArendi Therapeutics
Molecure S.A. (formerly OncoArendi Therapeutics) is a publicly listed Polish biotechnology company developing first-in-class small molecule therapeutics for inflammatory, fibrotic, and neoplastic diseases, with clinical-stage assets OATD-01 and OATD-02 serving patients with high unmet medical need.
- Company typePrivate
- Founded2012
- HeadquartersWysokie Mazowieckie, Poland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What OncoArendi Therapeutics does
Molecure S.A. (formerly OncoArendi Therapeutics until a March 2022 rebrand) is a publicly listed Polish biotechnology company focused on discovering, developing, and commercialising first-in-class small molecule therapeutics for neoplastic, inflammatory, and fibrotic diseases with significant unmet medical need. Founded in 2012 and headquartered in Wysokie Mazowieckie, Poland, the company trades on the Warsaw Stock Exchange under ticker OAT and operates with a clinical-stage workforce of 51-100 employees. Its lead programmes, OATD-01 and OATD-02, target inflammatory and fibrotic diseases, supported by an in-house discovery pipeline of unique and unexplored protein targets that was rationalised from five to three discovery-stage programs in October 2024.
The company's technological base combines in-house medicinal chemistry, biology, and discovery capabilities with novel target biology sourced from partnerships with leading universities worldwide, plus a cutting-edge small molecule mRNA targeting discovery platform. The approach is to identify and validate protein and mRNA targets that drive disease progression and modulate them with first-in-class small molecules, aiming to stop or reverse disease where existing therapies are inadequate. In January 2026 the company closed its RNA program and concentrated resources on its most commercially promising clinical assets, signalling a portfolio-focus pivot.
Molecure is pre-revenue with both lead candidates still in clinical development; pricing details are not publicly disclosed and there is no commercial product on market. The business model relies on equity capital via the public market, supplemented historically by non-dilutive grant funding from Poland's National Center for Research and Development (NCBiR), the Medical University of Warsaw, and EU structural funds, alongside a Seed/Series 1-2 financing history (aggregate disclosed funding roughly $16.5 million through 2017). Future monetisation is expected to follow standard pharmaceutical channels upon regulatory approval, with management including co-founder and Director of Chemistry Jacek Olczak, Chief Medical Officer Samson Fung, and President & CEO Marcin Szumowski.
OncoArendi Therapeutics firmographics
Firmographics- Name
- OncoArendi Therapeutics
- Legal name
- Molecure S.A.
- Website
- https://oncoarendi.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Molecure S.A. (formerly OncoArendi Therapeutics) is a publicly listed Polish biotechnology company developing first-in-class small molecule therapeutics for inflammatory, fibrotic, and neoplastic diseases, with clinical-stage assets OATD-01 and OATD-02 serving patients with high unmet medical need.
- Ownership category
- akta.pro rank
OncoArendi Therapeutics industry classification
Industry- Product category
- Clinical-stage Drug Discovery
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)
Keywords
Where OncoArendi Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Wysokie Mazowieckie
- HQ country
- Poland
- HQ region
- Europe
Markets served
OncoArendi Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Distribution channels1 record
Marketing channels4 records
OncoArendi Therapeutics product offering
Product offeringCore offering
Molecure (formerly OncoArendi Therapeutics) discovers and develops first-in-class small molecule drugs for the treatment of neoplastic, inflammatory, and fibrotic diseases with unmet medical need. Its core pipeline comprises clinical-stage drug candidates OATD-01 and OATD-02, supported by an in-house medicinal chemistry and biology discovery capability and a small molecule mRNA targeting discovery platform that identifies and validates novel protein and mRNA targets.
Product overview
Molecure (formerly OncoArendi Therapeutics) is an innovative biotechnology company discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company operates a diversified pipeline consisting of clinical-stage programs OATD-01 and OATD-02 for inflammatory and fibrotic diseases, alongside a cutting-edge small molecule mRNA targeting discovery platform. The company utilizes its in-house medicinal chemistry and biology capabilities to identify and validate unexplored protein and mRNA targets, modulating their activity with first-in-class small molecule drugs. The pipeline also includes discovery-stage protein target programs. In 2026, the company announced closure of its RNA program to focus on the most commercially promising projects.
Differentiator
Problem solved
Functional benefit
Products and services
- OATD-01 A clinical-stage drug candidate targeting inflammatory and fibrotic diseases, forming part of Molecure's focused therapeutic strategy for diseases with significant unmet medical need.
- OATD-02 A clinical-stage drug candidate for inflammatory and fibrotic diseases, part of Molecure's core clinical portfolio alongside OATD-01.
Companies that use OncoArendi Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
OncoArendi Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
OncoArendi Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves7 records
Expansion highlights4 records
OncoArendi Therapeutics competitors and assessment
Company assessmentDirect peers
- Evotec SE: German drug discovery and development company with a similar model of medicinal chemistry-driven small molecule discovery partnerships; comparable in scale and pre-clinical/early-clinical focus.
- Zealand Pharma: Danish clinical-stage biotech developing innovative therapeutics including small molecules and peptides; comparable European biotech with similar pipeline-stage profile.
- Galapagos NV: Belgian clinical-stage biotech focused on small molecule drug discovery in inflammatory and fibrotic diseases, with comparable pipeline depth and European listing (Nasdaq/AMS).
- PureTech Health: UK-listed biotech developing first-in-class therapeutics, often in inflammatory and fibrotic disease, with a similar model of platform-driven drug discovery.
Broad incumbents
- Orion Corporation: Finnish pharmaceutical company active in small molecule drug development, including specialty and inflammatory disease areas; broader portfolio but overlapping therapeutic focus.
- Recordati S.p.A. Italian specialty pharma with established inflammatory and rare disease franchises; comparable EU pharma peer with small molecule capabilities.
Emerging players
- Silence Therapeutics: UK biotech developing RNA-targeting therapeutics (siRNA); directly relevant as a peer in the small-molecule-RNA targeting space Molecure exited in 2026.
- AbCellera Biologics: Public clinical-stage biotech developing therapeutic antibodies; different modality but comparable mid-stage clinical pipeline and discovery platform orientation.
- Schrödinger, Inc. US computational chemistry/molecular modeling platform for small molecule drug discovery; comparable computational-discovery angle and peer for Molecure's cheminformatics approach.
Regional players
- Celon Pharma S.A. Polish clinical-stage biotech listed on the WSE developing small molecule drugs; comparable Central European peer in size, listing venue, and clinical-stage focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
OncoArendi Therapeutics social profiles
Digital presenceOncoArendi Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
OncoArendi Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
OncoArendi Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OncoArendi Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OncoArendi Therapeutics
What does OncoArendi Therapeutics do?
Molecure (formerly OncoArendi Therapeutics) discovers and develops first-in-class small molecule drugs for the treatment of neoplastic, inflammatory, and fibrotic diseases with unmet medical need. Its core pipeline comprises clinical-stage drug candidates OATD-01 and OATD-02, supported by an in-house medicinal chemistry and biology discovery capability and a small molecule mRNA targeting discovery platform that identifies and validates novel protein and mRNA targets.
Is OncoArendi Therapeutics a public or private company?
OncoArendi Therapeutics is a private company. It is classified as public and is currently operating.
When was OncoArendi Therapeutics founded?
OncoArendi Therapeutics was founded in 2012. It employs 51 to 100 people.
Where is OncoArendi Therapeutics based?
OncoArendi Therapeutics is headquartered in Wysokie Mazowieckie, Poland, in the Europe region.
Who are OncoArendi Therapeutics's main competitors?
Direct peers on record are Evotec SE, Zealand Pharma, Galapagos NV and PureTech Health. Broad incumbents are Orion Corporation and Recordati S.p.A.. Emerging players are Silence Therapeutics, AbCellera Biologics and Schrödinger, Inc.. Celon Pharma S.A. is listed as a regional player.
Does OncoArendi Therapeutics have an API?
No public API is recorded for OncoArendi Therapeutics.
What industry is OncoArendi Therapeutics in?
OncoArendi Therapeutics's product category is Clinical-stage Drug Discovery. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325412 and its SIC code is 2834.